Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AAV2-sFLT01 · 1 trial · 10 indications
| Arm | Type | Description |
|---|---|---|
| 2 x 10^8 vector genomes (vg) AAV2-sFLT01 | EXPERIMENTAL | - |
| 2 x 10^9 vector genomes (vg) AAV2-sFLT01 | EXPERIMENTAL | - |
| 6 x 10^9 vector genomes (vg) AAV2-sFLT01 | EXPERIMENTAL | - |
| 2 x 10^10 vector genomes (vg) AAV2-sFLT01 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AAV2-sFLT01 | BIOLOGICAL | 2 x 10\^8 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL. |
Inclusion Criteria: * Choroidal neovascular membrane (CNV) secondary to AMD, as confirmed by the patient's medical history and a documented diagnosis of CNV. * Distance BCVA of 20/100 or worse in the study eye. * The fellow eye must have distance BCVA of 20/400 or better. * The study eye, i.e., the...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 7 | PHASE3 | Surabgene Lomparvovec, RGX-314, ABBV-6628 |
| Ocular Therapeutix Inc | OCUL | 3 | PHASE3 | OTX-TKI |
| 4D Molecular Therapeutics, Inc. | FDMT | 3 | PHASE3 | 4D-150 |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE3 | Aflibercept, Pozelimab, Cemdisiran |
| Novartis AG Sponsored ADR | NVS | 5 | PHASE2 | Iptacopan, GT005, FWY003 |
| EyePoint, Inc. | EYPT | 2 | PHASE3 | EYP-1901 |
| Kodiak Sciences, Inc. | KOD | 1 | PHASE3 | Tarcocimab tedromer, Tabirafusp tedromer |
| Hoffmann-La Roche | RHHBY | 10 | PHASE3 | Ranibizumab, Susvimo, RO7965032, OpRegen, Faricimab |
| Outlook Therapeutics, Inc. | OTLK | 1 | PHASE3 | ONS-5010 |
| Adverum Biotechnologies, Inc. | ADVM | 4 | PHASE3 | Ixo-vec, ADVM-022 |
| Apellis Pharmaceuticals, Inc. | APLS | 1 | PHASE2 | APL-3007 |
| Amgen Inc. | AMGN | 1 | PHASE3 | ABP 938, Aflibercept |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-81201887 |
| Ocugen Inc | OCGN | 1 | PHASE3 | OCU410 |
| Alcon AG | ALC | 1 | PHASE1 | AR-14034 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE1 | SAR402663 |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE1 | ARO-033 |
| Bayer | BAYRY | 2 | - | Aflibercept |
AAV2-sFLT01 is an investigational gene therapy developed by Sanofi for neovascular age-related macular degeneration, a form of macular degeneration. It is designed to deliver a therapeutic gene directly to the eye. It has been studied in a single Phase 1 clinical trial and is not approved for any indication.
AAV2-sFLT01 was studied for the treatment of neovascular age-related macular degeneration, often called wet AMD, a condition in which abnormal blood vessels grow under the retina. The Phase 1 trial enrolled patients with this condition. It remains an investigational therapy and is not approved for clinical use.
AAV2-sFLT01 is being developed by Sanofi, which trades on the New York Stock Exchange under the ticker SNY. Sanofi sponsored the Phase 1 study of the therapy in patients with neovascular age-related macular degeneration. No other developer is listed for this asset.
AAV2-sFLT01 is in Phase 1 development. It has completed one Phase 1 clinical trial, and no active trials are currently listed. The therapy remains investigational and has not been approved by the FDA for any indication.
AAV2-sFLT01 has been evaluated in one completed Phase 1 trial, NCT01024998, titled a safety and tolerability study in patients with neovascular age-related macular degeneration. The trial enrolled 19 patients in the United States and included a controlled design. No other trials are listed.